Vir Biotechnology tumbles on $150 mln stock sale

** Vir Biotechnology's VIR.O shares tumble 15.7% to $10.22 before the bell after $150 mln overnight follow-on priced

** VIR late Thurs announced 15 mln shares at $10, a 17.5% discount to last sale

** Leerink, Morgan Stanley and Evercore bookrunners

** On Mon, VIR's stock jumped nearly 12% to close at $13.64 after co said its chronic hepatitis delta (CHD) therapy met primary endpoint in Phase 3 trial

** Last month, co inked up to $1.9 bln licensing deal with Gilead GILD.O for three candidates targeting selected solid tumor-associated antigens

** VIR intends to use net offering proceeds to fund pre-commercial activities for its CHD program, investments in its T-cell engager (TCE) oncology platform, among other purposes, per the prospectus

** San Francisco, California-based VIR has ~171.3 mln shares outstanding; through Thurs, stock doubled YTD

** All 9 analysts are bullish on the stock and their median PT is $23, per LSEG data